{"schema_version":"1.0","type":"article","title":"Centanafadine’s Phase 3b Win: Why ADHD Treatment Is Moving Beyond Discipline and Toward Neurobiology","url":"https://drugnews.com.tw/articles/2026-07-01-adhd-centanafadine-phase3b-en.html","markdown_url":"https://drugnews.com.tw/articles/2026-07-01-adhd-centanafadine-phase3b-en.md","lang":"en","date":"2026-07-01","publish_at":"2026-07-01T10:30:00+08:00","updated_at":"2026-07-01","category":"商業分析系列","topic":"商業分析系列","tags":["ADHD","centanafadine","Otsuka","clinical data","neuroscience","non-stimulant ADHD therapy","Taiwan biotech","drug development"],"summary":"Otsuka’s centanafadine has reported positive Phase 3b data in adults with ADHD and comorbid anxiety. The FDA has accepted the NDA and granted priority review, making the program a useful lens for how ADHD treatment is shifting from behavioral stigma toward more precise neurobiological intervention.","key_points":[],"facts":[],"sections":["01 | ADHD Is Not Just Hyperactivity. Anxiety and Emotional Burden Often Amplify the Disease","02 | Centanafadine’s Key Feature Is Not Just Efficacy. It Is the Simultaneous Regulation of Three Neurotransmitter Pathways","03 | Extended Release Matters: ADHD Does Not Exist Only During Class or Office Hours","04 | ADHD Treatment Is Not About Making Children “Behave.” It Is About Giving the Brain a Chance to Function","05 | Taiwan’s ADHD Medication Access: What to Watch","Conclusion | What Should Be Abandoned Is Not the Child, but the Old Assumption That ADHD Is a Character Problem","References"],"references":[{"title":"[Otsuka Announces FDA Acceptance and Priority Review of New Drug Application for Centanafadine for the Treatment of ADHD in Children, Adolescents, and Adults]","source":"","date":"","url":"https://www.otsuka-us.com/"},{"title":"[Otsuka Announces Positive Phase 3b Results for Centanafadine in Adults with ADHD and Comorbid Anxiety]","source":"","date":"","url":"https://www.otsuka-us.com/"},{"title":"[Centanafadine Demonstrates Statistically Significant, Clinically Relevant Improvements in ADHD Symptoms]","source":"","date":"","url":"https://www.pharmacytimes.com/"}],"images":[{"alt":"ADHD with comorbid anxiety can amplify attention, emotion, and executive-function challenges","url":"https://drugnews.com.tw/assets/articles/adhd-centanafadine-phase3b-en/figure-01.png"},{"alt":"Centanafadine is designed to modulate norepinephrine, dopamine, and serotonin signaling pathways","url":"https://drugnews.com.tw/assets/articles/adhd-centanafadine-phase3b-en/figure-02.png"},{"alt":"Once-daily extended-release therapy aims to provide steadier symptom coverage across daily life","url":"https://drugnews.com.tw/assets/articles/adhd-centanafadine-phase3b-en/figure-03.png"},{"alt":"Taiwan ADHD medication access involves imported drugs, generics, supply stability, and regional licensing","url":"https://drugnews.com.tw/assets/articles/adhd-centanafadine-phase3b-en/figure-04.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/adhd-centanafadine-phase3b-en/cover.png","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-07-01）。Centanafadine’s Phase 3b Win: Why ADHD Treatment Is Moving Beyond Discipline and Toward Neurobiology。https://drugnews.com.tw/articles/2026-07-01-adhd-centanafadine-phase3b-en.html","disclaimer":"This article is intended for industry research and knowledge sharing only. It does not constitute investment, medical, fundraising, or individual stock advice.","translations":{"zh-Hant":"2026-07-01-adhd-centanafadine-phase3b.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}